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Abstract
Purpose The purpose of the study was to assess self-reported taste and smell perception after chemotherapy in breast cancer 
patients compared with women without cancer, and to assess whether taste and smell perception is associated with quality 
of life after the end of chemotherapy.
Methods We included 135 newly diagnosed breast cancer patients who completed chemotherapy and 114 women without 
cancer. Questionnaires on taste, smell, and quality of life were completed shortly after and 6 months after chemotherapy 
(patients) or at two moments with 6 months’ time window in between (comparisons).
Results Self-reported taste and smell perception were significantly lower in patients shortly after chemotherapy compared 
to the comparison group. Most patients recovered 6 months after chemotherapy, although patients who were still receiving 
trastuzumab then reported a lower taste and smell perception compared to patients who were not. A lower self-reported 
taste and smell were statistically significantly associated with a worse quality of life, social, emotional, and role functioning 
shortly after chemotherapy. Six months after chemotherapy, taste and smell were statistically significantly associated with 
quality of life, social and role functioning, but only in patients receiving trastuzumab.
Conclusions Most taste and smell alterations recovered within 6 months after the end of chemotherapy for breast cancer, 
but not for patients receiving trastuzumab. These results highlight the importance of monitoring taste and smell alterations 
during and after treatment with chemotherapy and trastuzumab, as they may impact quality of life.
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Introduction
Taste and smell alterations are amongst the most distressing 
side effects of chemotherapy treatment in cancer patients 
and may seriously impact everyday life of cancer patients 
[1]. Qualitative studies show that taste and smell alterations 
during chemotherapy have an impact on patient’s lives in 
terms of household roles (e.g., partners that take over gro-
cery shopping and cooking) and social interactions (e.g., 
not eating out or inviting friends for dinner) [2, 3]. Also 
quantitative studies have shown that cancer patients with an 
altered taste and/or smell during chemotherapy have a lower 
quality of life [4–7].
Previous research has shown that taste and smell altera-
tions are largely transient, and usually recover within the 
first three months after the end of chemotherapy [8–10]. 
However, some studies suggest that taste and smell may be 
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distorted well beyond the end of chemotherapy [11–13]. 
To date, there is not much known about factors that influ-
ence taste and smell perception after the end of chemo-
therapy, but potentially this is affected by the consequent 
treatment that patients receive. E.g., breast cancer patients 
treated with neo-adjuvant chemotherapy may still undergo 
surgery and/or radiotherapy, about 60–75% of patients 
receive hormonal therapy [14] and approximately 30% 
of patients receives trastuzumab [15, 16]. If, and to what 
extent these factors relate to taste and smell perception, 
and whether it is related to quality of life after the end of 
chemotherapy is currently unknown.
To understand more about the nature and impact of 
taste and smell changes after chemotherapy treatment, 
the aim of the current study was twofold. First, we 
assessed reported taste and smell changes shortly after, 
and 6 months after chemotherapy in breast cancer patients 
compared to a group of women without breast cancer. Sec-
ond, we aimed to determine the association between taste 
and smell perception and quality of life shortly after and 
6 months after chemotherapy.
Materials and methods
Participants
This study is part of the COBRA-study [17], an observa-
tional multi-center study among breast cancer patients dur-
ing chemotherapy and a comparison group of women with-
out cancer of similar age. Women with newly diagnosed, 
stage I–IIIB, operable breast cancer, who were scheduled 
to receive chemotherapy were recruited for this study in 
11 hospitals in the Netherlands. In addition, we recruited 
a comparison group of women without breast cancer. 
Participants for this comparison group were recruited 
via patients; patients were asked to distribute envelopes 
with study information to friends, acquaintances, and col-
leagues of similar age. If these friends/acquaintances/col-
leagues were interested in participating in the study, they 
were asked to contact the researchers who explained the 
study procedures. To be eligible for the patient or com-
parison group, participants had to be at least 18 years old 
and had to able to communicate in Dutch. For both groups, 
exclusion criteria were as follows: history of cancer, previ-
ous treatment with chemotherapy, pregnancy or the inten-
tion to get pregnant during the study period, dementia or 
other mental conditions that made it impossible to comply 
with study procedures. The protocol was approved by the 
Medical Ethical Committee of Wageningen University, 
Wageningen, the Netherlands. All participants provided 
written informed consent before enrolment.
Study design
We assessed self-reported taste and smell perception and 
quality of life at two moments. For breast cancer patients, 
this was within 1 month after the last chemotherapy cycle 
(T1) and approximately 6 months after the last chemo-
therapy cycle (T2). Most of the patients who received 
trastuzumab as part of their systemic treatment were still 
receiving this on T2 (n = 29 out of n = 31 patients receiv-
ing trastuzumab), but had completed the chemotherapy 
part of systemic treatment at T1.
In the comparison group, measurements took place at 
two moments that were approximately 6 months apart. 
In total, 135 patients and 114 controls were included in 
the analyses, see Fig. 1 for an overview flow chart of in- 
and excluded participants. Patients who did not fill in 
the questionnaires within 1 month after the last chemo-
therapy cycle (T1), or did not fill in the questionnaires 
within 5–8 months after the last chemotherapy cycle (T2) 
were excluded from the analyses (n = 7). On average, 
the time between the first and second measurement was 
207 ± 18 days (patients) and 194 ± 17 days (controls).
Measurements
Self‑reported taste and smell
The appetite, hunger, and sensory perception (AHSP) 
questionnaire was used to assess self-judgement of taste 
and smell perception [18]. The questionnaire consists of 
questions answered on a 5 point Likert scale. For this 
study, we used the taste (8 items, score range 8–40) and 
smell (6 items, range 6–30) scale. A higher score corre-
sponds to a more positive judgement about current taste 
and smell perception.
To assess the prevalence of taste and smell changes in 
patients, two questions were added from the 16-item taste 
and smell questionnaire [19]: (1) Have you noticed any 
changes in your sense taste compared to before chemo-
therapy? (2) Have you noticed any changes in your sense 
smell compared to before chemotherapy? Answer possi-
bilities: no, it is the same; yes, it is better; yes, it is worse.
Quality of life
The EORTC QLQ-C30 was used to assess health-related 
quality of life [20]. For this study, we used the scales for 
global quality of life, and the functional scales for social, 
role and emotional functioning. Questions were asked on a 
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4-point Likert scale, and were transformed to scales from 0 
to 100 according to the questionnaire guidelines [21]. For 
all quality of life scales, a higher score corresponds to a 
better quality of life or level of functioning.
Demographic and clinical characteristics
All participants filled out a general questionnaire for demo-
graphic information which included age, smoking status 
(current, former, never), educational level (low, middle, 
high), and living situation (alone, with partner and/or chil-
dren). Information on stage of disease at diagnosis (stage 
I, II, or III) and treatment (neo- or adjuvant chemotherapy, 
type of chemotherapy, hormone treatment yes/no, trastu-
zumab yes/no) were obtained from patients’ medical records. 
Chemotherapy regimens were categorized to combined and 
sequential regimes. Combined regimes included schemes 
where all different components were administered together 
during all cycles, such as TAC (6 × docetaxel, doxoru-
bicin and cyclophosphamide every 3 weeks). Sequential 
regimes included schemes where different components 
were administered in different cycles such as ACP (ACP: 
4 × adriamycin and cyclophosphamide every 3 weeks fol-
lowed by 12 × paclitaxel weekly).
Data analysis
Demographic, clinical variables and prevalence of taste and 
smell changes are presented as mean ± SD or n (%). We 
used a linear mixed model analysis to assess differences in 
the AHSP subscales for taste and smell and quality of life 
outcomes over time and between groups. Time (T1 and T2) 
and group (patient or comparison group) were included in 
the model as fixed and participants as random factor.
Analysis of covariance was used to assess associations 
between demographic, clinical variables (stage of disease, 
adjuvant/neo-adjuvant treatment, type of chemotherapy, hor-
mone treatment, and trastuzumab) and taste and smell on 
both time points separately. Analysis of covariance was also 
used to assess the association between taste, smell, and qual-
ity of life. Relevant covariates were included in the models 
based on the literature and change of regression coefficient. 
Fig. 1  Flow chart of participants of the COBRA study, an observational multi-center study among breast cancer patients during chemotherapy 
and a comparison group of women without cancer of similar age
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Variables that changed the regression coefficient ≥ 10% 
in the adjusted model compared to the crude model were 
included in the final model. Final models were adjusted for 
age. Possible effect modifiers were assessed by including 
interactions in the model. Variables assessed as effect modi-
fiers were as follows: adjuvant/neo-adjuvant treatment, type 
of chemotherapy (combined vs. sequential), hormone treat-
ment (yes vs. no), and trastuzumab (yes vs. no). Statistical 
analyses were performed using IBM SPSS statistics version 
23. A p value < 0.05 was considered statistically significant.
Results
Demographic and clinical characteristics of the patient 
and the control group are shown in Table 1. Breast can-
cer patients had a slightly lower age and higher BMI than 
the women without breast cancer. Furthermore, the patient 
group had more current smokers and fewer former smokers 
than the comparison group. The groups were similar in edu-
cation level and living situation. Most patients had a stage II 
tumor and were treated with adjuvant chemotherapy.
Both shortly after (T1) and half a year after chemotherapy 
(T2), breast cancer patients reported a lower taste perception 
compared to the comparison group (Fig. 2a). The compari-
son group remained stable, while, in the patient group, self-
reported taste perception improved over time. Results were 
similar for self-reported smell perception (Fig. 2b), although 
there was no significant difference for smell at T2 between 
the patient and the comparison group.
At T1 (shortly after chemotherapy), 65% of patients 
reported their taste perception as worse compared to before 
chemotherapy, 3% reported a better taste perception and 32% 
reported their taste perception as unchanged. Half a year 
later (T2), 16% of patients reported a worse taste perception, 
8% a better taste perception and 76% reported their taste to 
be the same as before chemotherapy.
For smell at T1, 19% of patients reported their smell per-
ception to be worse; 16% reported a better smell percep-
tion, and 65% reported their smell to be the same as before 
chemotherapy. Half a year later (T2), only 3% reported a 
worse smell perception, 12% better, and 85% reported their 
smell perception to be the same as before chemotherapy.
Both shortly after (T1) and half a year after chemo-
therapy (T2), age, BMI, smoking status, living situation, 
education level, stage of disease, receiving adjuvant or 
neo-adjuvant treatment, type of chemotherapy and receiv-
ing hormone treatment were all not associated with self-
reported taste or smell (data not shown). At T2, patients 
receiving trastuzumab (n = 31) scored 2.6 points lower 
on the taste scale (β = − 2.6, 95% CI − 4.17; − 1.08, 
p = 0.001) and 2.0 points lower smell scale (β = − 2.0, 
95% CI − 3.12; − 0.87, p = 0.001) compared to patients 
not receiving trastuzumab (n = 104).
Global quality of life was significantly lower in the 
patient group compared to the comparison group at both 
time points (Fig. 3a), but significantly improved half a year 
after chemotherapy. These patterns between groups and 
over time were similar for role functioning and social func-
tioning (Fig. 3b, c). For emotional functioning, patients 
scored lower compared to the comparison group at T1 
and T2, and this did not improve half a year after chemo-
therapy (Fig. 3d).
Table 1  Demographic and clinical characteristics of women without 
breast cancer (comparison group), and women with breast cancer 
(patients) presented as mean (SD) or n (%)
a 1 missing for patient group
Comparison n = 114 Patients n = 135
Demographic characteristics
 Age (years) 55.4 (10.2) 52.5 (9.1)
 BMI (kg/m2) 24.9 (3.5) 26.0 (4.0)
 Smokinga
  Current 10 (9) 21 (15)
  Former 62 (54) 56 (42)
  Never 42 (37) 57 (43)
 Educationa
  Lower 9 (8) 12 (9)
  Middle 32 (28) 42 (31)
  Higher 73 (64) 80 (60)
 Living  situationa
  Alone 15 (13) 16 (12)
  With partner and/or 
children
99 (87) 118 (88)
Clinical characteristics
 Adjuvant chemotherapy 83 (61)
 Neo-adjuvant chemo-
therapy
52 (39)
 Stage
  I 36 (27)
  II 79 (59)
  III 19 (14)
 Chemotherapy
  Combined treatment 62 (46)
  Split treatment 73 (54)
 Hormone  treatmenta
  Yes 104 (78)
  No 30 (22)
 Trastuzumab
  Yes 31 (23)
  No 104 (77)
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Associations between taste, smell, and quality of life 
shortly and half a year after chemotherapy
In patients, better reported taste and smell shortly after 
chemotherapy (T1) were statistically significantly associated 
with better global quality of life, role functioning, social 
functioning and emotional functioning (Table 2). 
Half a year after the end of chemotherapy, the asso-
ciation between taste, smell, and global quality of life, 
role functioning and social functioning, was different for 
patients receiving trastuzumab versus patients not receiv-
ing trastuzumab (Table 3). Only in patients who received 
trastuzumab, better reported taste and smell perception 
were statistically significantly associated with a better 
global quality of life; in addition, better reported taste 
and smell were associated with better role functioning 
and social functioning. In patients not treated with trastu-
zumab, reported taste and smell perception were not statis-
tically significantly associated with global quality of life, 
role functioning, and social functioning.
Fig. 2  Taste and smell scores 
(mean ± SD) of the AHSP 
questionnaire over time for the 
patient and comparison group. 
T1 represents the first measure-
ment (comparison) and shortly 
after chemotherapy (patients), 
T2 represents 6 months after the 
first measurement (comparison) 
or ~ 6 months after the end of 
chemotherapy (patients). *indi-
cates a significant difference at 
p < 0.05
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Fig. 3  Global quality of life (a) and function scales (b social, c role, 
and d emotional functioning) of the EORTC-QLQ-C30 (mean ± SD) 
over time for the patient and comparison group. T1 represents the first 
measurement which for the patients was done shortly after chemo-
therapy; T2 is the second measurement, which took place ~ 6 months 
after the first measurement. *indicates a significant difference at 
p < 0.05
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Discussion
In this study, we assessed reported taste and smell changes 
shortly after, and 6 months after chemotherapy in breast 
cancer patients compared to a group of women without 
breast cancer. Furthermore, we determined the associa-
tion between taste and smell perception and quality of life 
shortly after and 6 months after chemotherapy.
In line with previous studies in breast cancer patients, 
we showed that taste and smell perception are altered 
shortly after the end of chemotherapy, but recovered in the 
6 months after the end of chemotherapy for most patients 
[8, 9]. The prevalence of taste (68%) and smell alterations 
(35%) shortly after chemotherapy are also within the range 
described in the previous literature for taste (45–84%) 
and smell (5–60%) [22]. Interestingly, half a year after 
chemotherapy self-reported taste and smell perception 
were lower in patients receiving trastuzumab compared to 
patients not treated with trastuzumab.
We found that lower taste and smell perception were 
associated with lower quality of life, which is in line with 
previous studies in cancer patients during chemotherapy [4, 
5, 23]. In addition, role and social functioning were associ-
ated with worsened taste and smell perception. Although 
these findings are associations, it is likely that changes in 
role functioning could indeed be a result of changes in taste 
and smell, e.g., role functioning may be affected because a 
partner needs to take over cooking, because cooking smells 
are being experienced by patients as offensive or nauseating 
[2, 23]. Problems with cooking are commonly reported in 
patients with olfactory dysfunction, as they have difficulties 
with smelling whether food is spoiled [24, 25]. In addition, 
research in the general population has shown that women 
with good smell function tend to have more active social 
lives than those with diminished smell function [26].
To the best of our knowledge, this is the first study that 
showed that taste or smell changes persist during the period 
of trastuzumab when the patients are no longer receiving 
chemotherapy. Our follow-up period started half a year after 
the end of chemotherapy, so we could not study whether 
these changes in taste and smell in trastuzumab-treated 
patients were also transient and recovered after trastuzumab 
ended. Therefore, a future project should assess taste and 
smell perception before, at several moments during and after 
the end of treatment with trastuzumab. This will give insight 
in whether these alterations might diminish or worsen over 
the trajectory, and whether these alterations recover after 
the end of treatment with trastuzumab. If future studies con-
firm our findings on trastuzumab and taste and smell, further 
mechanistic work is needed to understand how trastuzumab 
affects the sensory system. For chemotherapy, the general 
hypothesis is that it acts on rapidly dividing cells, and ther-
apy may therefore also impact the taste and smell receptor 
cells that have a turnover rate of 1 week to a month [27, 28]. 
Table 2  The association between taste, smell, and quality of life 
outcomes in breast cancer patients shortly after chemotherapy (T1), 
adjusted for age
β represents the difference in quality of life outcome per 1 unit higher 
score on taste or smell as assessed with the AHSP questionnaire
β SE p value 95% CI
Taste
 Global quality of life 0.99 0.26 < 0.001 0.47; 1.51
 Role functioning 1.74 0.36 < 0.001 1.03; 2.44
 Social functioning 1.14 0.32 < 0.001 0.51; 1.77
 Emotional functioning 0.79 0.28 < 0.005 0.24; 1.35
Smell
 Global quality of life 1.09 0.44 0.02 0.21; 1.96
 Role functioning 1.50 0.62 0.02 0.27; 2.74
 Social functioning 1.69 0.52 < 0.01 0.65; 2.72
 Emotional functioning 1.23 0.46 < 0.01 0.32; 2.14
Table 3  The association 
between taste, smell, and quality 
of life outcomes in breast cancer 
patients half a year after the end 
of chemotherapy, (T2) stratified 
for trastuzumab, adjusted for 
age
β represents the difference in quality of life outcome per 1 unit higher score on taste or smell as assessed 
with the AHSP questionnaire
Patients receiving trastuzumab 
(n = 31)
Patients not receiving trastuzumab 
(n = 104)
β SE p value 95% CI β SE p value 95% CI
Taste
 Global quality of life 2.52 0.77 < 0.01 0.92; 4.12 0.76 0.53 0.15 − 0.29; 1.81
 Role functioning 3.01 0.88 < 0.01 1.19; 4.82 0.24 0.77 0.76 − 1.29; 1.76
 Social functioning 3.47 0.93 < 0.001 1.56; 5.38 0.78 0.62 0.21 − 0.46; 2.01
Smell
 Global quality of life 3.11 1.16 0.013 0.72; 5.49 0.37 0.72 0.60 − 1.06; 1.81
 Role functioning 3.05 1.39 0.04 0.18; 5.92 − 0.29 1.04 0.78 − 2.36; 1.77
 Social functioning 4.18 1.42 < 0.01 1.25; 7.10 0.52 0.84 0.54 − 1.16; 2.20
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Objective measurements of taste and smell function could 
help to elucidate whether these alterations are due to actual 
dysfunction of the sense of taste and/or smell. Research has 
shown that a lower taste perception during chemotherapy 
in breast cancer patients is associated with a lower energy 
intake, specifically for protein and fat intake [17]. Poten-
tially, patients who are treated with trastuzumab have a lower 
energy intake for a prolonged period of time, which might 
have an impact on their nutritional status.
Although we did not perform objective or baseline smell 
or taste measurements in the complete patient and compari-
son group in the present study, we did collect these data 
in a subgroup of patients and control women (n = 28 per 
group, as reported in [29]). Those data show that before start 
of chemotherapy there are no differences in self-reported 
smell or taste perception, or in objective smell or taste meas-
urements, between patients and control women. This sug-
gests that the findings reported here reflect actual changes 
in taste perception in the patient group, rather than differ-
ences between the groups, or alterations in the patient group 
already at baseline.
Six months after the end of chemotherapy, the score on 
taste was 2.6 points lower, and on smell 2.0 points lower in 
patients receiving trastuzumab than in patients not receiv-
ing trastuzumab. Even though the differences were small, 
there was a significant association with quality of life at this 
time point in the patients receiving trastuzumab, which was 
not present among the patients not receiving trastuzumab. 
This suggests that, although reported differences in taste and 
smell are small, they may affect quality of life.
Unfortunately, there are currently no effective interven-
tions for taste and smell alterations in cancer patients. How-
ever, it is important to monitor these alterations over the 
treatment trajectory in breast cancer patients, in particular 
given that those changes may have an impact on quality of 
life and on nutritional status. After chemotherapy has ended, 
specifically patients who are treated with trastuzumab are a 
group of interest that warrants the attention of clinicians.
In conclusion, this study shows that most taste and smell 
alterations recover after chemotherapy for breast cancer, 
but importantly, not for patients who receive trastuzumab. 
Monitoring of changes in taste and smell may be warranted 
especially for patients receiving trastuzumab as they may 
potentially impact quality of life and nutritional status.
Data availability
The datasets analyzed during the current study are available 
from the corresponding author on reasonable request.
Acknowledgements This study was funded by the Dutch Cancer 
Society (Grant Numbers UW2011-4987 and UW2011-5268) and Top 
Institute Food and Nutrition, a public–private partnership on precom-
petitive research in food and nutrition. The public partners are respon-
sible for the study design, data collection and analysis, decision to 
publish and preparation of the manuscript. The private partners have 
contributed to the project through regular discussion.
Compliance with ethical standards 
Conflict of interest The authors declare that they have no conflicts of 
interest.
Ethical approval All procedures performed in the study described in 
this manuscript were in accordance with the ethical standards of the 
institutional and/or national research committee.
Open Access This article is distributed under the terms of the Crea-
tive Commons Attribution 4.0 International License (http://creat iveco 
mmons .org/licen ses/by/4.0/), which permits unrestricted use, distribu-
tion, and reproduction in any medium, provided you give appropriate 
credit to the original author(s) and the source, provide a link to the 
Creative Commons license, and indicate if changes were made.
References
 1. Lindley C, McCune JS, Thomason TE, Lauder D, Sauls A, Adkins 
S, Sawyer WT (1999) Perception of chemotherapy side effects: 
cancer versus noncancer patients. Cancer Pract 7(2):59–65. https 
://doi.org/10.1046/j.1523-5394.1999.07205 .x
 2. de Vries YC, Helmich E, Karsten MDA, Boesveldt S, Winkels 
RM, van Laarhoven HWM (2016) The impact of chemosensory 
and food-related changes in patients with advanced oesophago-
gastric cancer treated with capecitabine and oxaliplatin: a quali-
tative study. Support Care Cancer 24(7):3119–3126. https ://doi.
org/10.1007/s0052 0-016-3128-z
 3. Bernhardson BM, Tishelman C, Rutqvist LE (2007) Chem-
osensory changes experienced by patients undergoing cancer 
chemotherapy: a qualitative interview study. J Pain Symptom 
Manag 34(4):403–412. https ://doi.org/10.1016/j.jpain symma 
n.2006.12.010
 4. Gamper EM, Giesinger JM, Oberguggenberger A, Kemmler G, 
Wintner LM, Gattringer K, Sperner-Unterweger B, Holzner B, 
Zabernigg A (2012) Taste alterations in breast and gynaecologi-
cal cancer patients receiving chemotherapy: prevalence, course of 
severity, and quality of life correlates. Acta Oncol 51(4):490–496. 
https ://doi.org/10.3109/02841 86x.2011.63355 4
 5. Zabernigg A, Gamper EM, Giesinger JM, Rumpold G, Kemmler 
G, Gattringer K, Sperner-Unterweger B, Holzner B (2010) Taste 
alterations in cancer patients receiving chemotherapy: a neglected 
side effect? Oncologist 15(8):913–920. https ://doi.org/10.1634/
theon colog ist.2009-0333
 6. Ponticelli E, Clari M, Frigerio S, De Clemente A, Bergese I, Scav-
ino E, Bernardini A, Sacerdote C (2017) Dysgeusia and health-
related quality of life of cancer patients receiving chemotherapy: a 
cross-sectional study. Eur J Cancer Care. https ://doi.org/10.1111/
ecc.12633 
 7. Turcott JG, Juárez-Hernández E, De La Torre-Vallejo M, Sánchez-
Lara K, Luvian-Morales J, Arrieta O (2016) Value: changes in the 
detection and recognition thresholds of three basic tastes in lung 
cancer patients receiving cisplatin and paclitaxel and its associa-
tion with nutritional and quality of life parameters. Nutr Cancer 
68(2):241–249. https ://doi.org/10.1080/01635 581.2016.11440 75
34 Breast Cancer Research and Treatment (2018) 170:27–34
1 3
 8. Boltong A, Aranda S, Keast R, Wynne R, Francis PA, Chirgwin 
J, Gough K (2014) A prospective cohort study of the effects of 
adjuvant breast cancer chemotherapy on taste function, food lik-
ing, appetite and associated nutritional outcomes. PLoS ONE. 
https ://doi.org/10.1371/journ al.pone.01035 12
 9. Steinbach S, Hummel T, Böhner C, Berktold S, Hundt W, Kriner 
M, Heinrich P, Sommer H, Hanusch C, Prechtl A, Schmidt B, 
Bauerfeind I, Seck K, Jacobs VR, Schmalfeldt B, Harbeck N 
(2009) Qualitative and quantitative assessment of taste and smell 
changes in patients undergoing chemotherapy for breast cancer or 
gynecologic malignancies. J Clin Oncol 27(11):1899–1905. https 
://doi.org/10.1200/jco.2008.19.2690
 10. Ijpma I, Renken RJ, Gietema JA, Slart RHJA, Mensink MGJ, 
Lefrandt JD, Ter Horst GJ, Reyners AKL (2016) Changes in 
taste and smell function, dietary intake, food preference, and 
body composition in testicular cancer patients treated with cis-
platin-based chemotherapy. Clin Nutr. https ://doi.org/10.1016/j.
clnu.2016.10.013
 11. Ijpma I, Renken RJ, Gietema JA, Slart RHJA, Mensink MGJ, 
Lefrandt JD, Ter Horst GJ, Reyners AKL (2016) Taste and smell 
function in testicular cancer survivors treated with cisplatin-
based chemotherapy in relation to dietary intake, food prefer-
ence, and body composition. Appetite 105:392–399. https ://doi.
org/10.1016/j.appet .2016.06.010
 12. Cohen J, Laing DG, Wilkes FJ, Chan A, Gabriel M, Cohn RJ 
(2014) Taste and smell dysfunction in childhood cancer survivors. 
Appetite 75:135–140. https ://doi.org/10.1016/j.appet .2014.01.001
 13. Jensen SB, Mouridsen HT, Bergmann OJ, Reibel J, Brünner N, 
Nauntofte B (2008) Oral mucosal lesions, microbial changes, 
and taste disturbances induced by adjuvant chemotherapy in 
breast cancer patients. Oral Surg 106(2):217–226. https ://doi.
org/10.1016/j.tripl eo.2008.04.003
 14. Burstein HJ, Temin S, Anderson H, Buchholz TA, Davidson 
NE, Gelmon KE, Giordano SH, Hudis CA, Rowden D, Solky 
AJ, Stearns V, Winer EP, Griggs JJ (2014) Adjuvant endocrine 
therapy for women with hormone receptor-positive breast cancer: 
American society of clinical oncology clinical practice guideline 
focused update. J Clin Oncol 32(21):2255–2269. https ://doi.
org/10.1200/jco.2013.54.2258
 15. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire 
WL (1987) Human-breast cancer—correlation of relapse and 
survival with amplification of the HER-2 neu oncogene. Science 
235(4785):177–182. https ://doi.org/10.1126/scien ce.37981 06
 16. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith 
DE, Levin WJ, Stuart SG, Udove J, Ullrich A, Press MF (1989) 
Studies of the HER-2/neu proto-oncogene in human breast and 
ovarian cancer. Science 244(4905):707–712
 17. de Vries YC, van den Berg MMGA, de Vries JHM, Boesveldt 
S, de Kruif JTCM, Buist N, Haringhuizen A, Los M, Sommeijer 
DW, Timmer-Bonte JHN, van Laarhoven HWM, Visser M, Kamp-
man E, Winkels RM (2017) Differences in dietary intake during 
chemotherapy in breast cancer patients compared to women with-
out cancer. Support Care Cancer. https ://doi.org/10.1007/s0052 
0-017-3668-x
 18. Mathey MFAM, De Jong N, De Groot CPGM, De Graaf C, Van 
Staveren WA (2001) Assessing appetite in dutch elderly with the 
appetite, hunger and sensory perception (AHSP) questionnaire. J 
Nutr 5(1):22–26
 19. Heald AE, Pieper CF, Schiffman SS (1998) Taste and smell com-
plaints in HIV-infected patients. AIDS 12(13):1667–1674. https 
://doi.org/10.1097/00002 030-19981 3000-00015 
 20. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, 
Duez NJ, Filiberti A, Flechtner H, Fleishman SB, Haes JCJMD, 
Kaasa S, Klee M, Osoba D, Razavi D, Rofe PB, Schraub S, 
Sneeuw K, Sullivan M, Takeda F (1993) The European organiza-
tion for research and treatment of cancer QLQ-C30: a quality-
of-life instrument for use in international clinical trials in oncol-
ogy. J Natl Cancer Inst 85(5):365–376. https ://doi.org/10.1093/
jnci/85.5.365
 21. Fayers PM, Aaronson NK, Bjordal K, Groenvold M, Curran D, 
Bottomley A (2001) The EORTC QLQ-C30 scoring manual, 3rd 
edn. European Organisation for Research and Treatment of Can-
cer, Brussels
 22. Gamper EM, Zabernigg A, Wintner LM, Giesinger JM, Ober-
guggenberger A, Kemmler G, Sperner-Unterweger B, Holzner B 
(2012) Coming to your senses: detecting taste and smell altera-
tions in chemotherapy patients. a systematic review. J Pain Symp-
tom Manag 44(6):880–895. https ://doi.org/10.1016/j.jpain symma 
n.2011.11.011
 23. Brisbois TD, De Kock IH, Watanabe SM, Baracos VE, Wis-
mer WV (2011) Characterization of chemosensory alterations 
in advanced cancer reveals specific chemosensory phenotypes 
impacting dietary intake and quality of life. J Pain Symptom 
Manag 41(4):673–683. https ://doi.org/10.1016/j.jpain symma 
n.2010.06.022
 24. Croy I, Nordin S, Hummel T (2014) Olfactory disorders and qual-
ity of life-an updated review. Chem Senses 39(3):185–194. https 
://doi.org/10.1093/chems e/bjt07 2
 25. Philpott CM, Boak D (2014) The impact of olfactory disorders in 
the United Kingdom. Chem Senses 39(8):711–718. https ://doi.
org/10.1093/chems e/bju04 3
 26. Boesveldt S, Yee JR, McClintock MK, Lundström JN (2017) 
Olfactory function and the social lives of older adults: a matter of 
sex. Sci Rep. https ://doi.org/10.1038/srep4 5118
 27. Breslin Paul AS (2013) An evolutionary perspective on food 
and human taste. Curr Biol 23(9):R409–R418. https ://doi.
org/10.1016/j.cub.2013.04.010
 28. Lawless HT, Heymann H (2010) Physiological and psychological 
foundations of sensory function. In: Sensory evaluation of food: 
principles and practices. Springer, New York, p 19–56. https ://doi.
org/10.1007/978-1-4419-6488-5_2
 29. de Vries YC, Winkels RM, van den Berg MMGA, de Graaf C, 
Kelfkens CS, de Kruif JTCM, Göker E, Grosfeld S, Sommei-
jer DW, van Laarhoven HWM, Kampman E, Boesveldt S (2018) 
Altered food preferences and chemosensory perception during 
chemotherapy in breast cancer patients: a longitudinal comparison 
with healthy controls. In: Food quality and preference, vol 63. p 
135–143. https ://doi.org/10.1016/j.foodq ual.2017.09.003
